Get the Stockscreener App
52.41
0.65%
0.34
Pre-market:
52.45
0.04
+0.08%
Royalty Pharma Plc stock is traded at $52.41, with a volume of 3.81M.
It is up +0.65% in the last 24 hours and up +4.82% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$52.07
Open:
$52
24h Volume:
3.81M
Relative Volume:
1.17
Market Cap:
$23.23B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
27.45
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+1.37%
1M Performance:
+4.82%
6M Performance:
+35.60%
1Y Performance:
+53.02%
1-Day Range:
$51.81
$52.62
1-Week Range:
$51.58
$53.47
52-Week Range:
$32.15
$53.47
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
52.41 | 23.08B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC $RPRX Shares Acquired by Cullen Frost Bankers Inc. - MarketBeat
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance - Insider Monkey
Royalty Pharma plc (RPRX) Investor Outlook: Strong Buy Ratings and Solid Growth Prospects - DirectorsTalk Interviews
Qsemble Capital Management LP Invests $2.88 Million in Royalty Pharma PLC $RPRX - MarketBeat
Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance UK
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead - Seeking Alpha
Royalty Pharma EVP Urist sells $726,137 in shares - Investing.com UK
Royalty Pharma EVP Urist sells $726,137 in shares By Investing.com - Investing.com Nigeria
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan - Stock Titan
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden - Stock Titan
Understanding the Setup: (RPRX) and Scalable Risk - Stock Traders Daily
Press Release: Royalty Pharma Declares Second Quarter 2026 Dividend - Moomoo
Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares - Stock Titan
[144] Royalty Pharma plc SEC Filing - Stock Titan
Capital International (RPRX) amendment shows 8.8% stake in Royalty Pharma - Stock Titan
Royalty Pharma stock hits 52-week high at 52.16 USD By Investing.com - Investing.com Nigeria
RPRX: Expanding royalty financing, robust pipeline, and strong capital position drive future growth - TradingView
Royalty Pharma stock hits 52-week high at 52.16 USD - Investing.com India
Royalty pharma – funding the next generation of medicines - Livewire Markets
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Healthcare Giant with a Promising 16.66% Potential Upside - DirectorsTalk Interviews
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com Australia
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts - Morningstar
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma - Morningstar
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):